Tridentify signs LOI with Intrance Medical Systems for purchase, sell of its safeguarding services
Gothenburg, Sweden – Tridentify AB has signed a letter of intent (LOI) with Intrance Medical Systems regarding purchase and delivery of the Tridentify Tracer Solution. The seller (Tridentify AB) has developed an advanced SaaS and IoT system for the real time monitoring and continuous stability control of pharmaceuticals in the cold chain.
The buyer (Intrance Medical Systems Inc) has developed a drug/device treatment system for patients suffering from Parkinson´s diseases in an advanced stage. The drug component is expected to be delivered internationally and need to be transported under refrigerated conditions.
The intended transaction involves the seller providing the monitoring system as a fee for service, covering safeguarding services of shipments of the pharmaceutical products used in the buyer´s clinical development program including clinics in the EU and the US.
Final commercial and legal terms will be negotiated in good faith with the mutual ambition to be completed by, at the latest September 1, 2023, unless both parties agree to an extension.
“Tridentify is delighted about the interest that Intrance Medical Systems has shown in our Tracer Solution. We are proud that Intrance is to become our first signed biomedical customer and that we will be able to support the development of a new Parkinson treatment in the US,” says Johan Stormlund, CEO at Tridentify.
Comment on this article below or via Twitter @IoTGN